MicroRNA-183-5p promotes the proliferation, invasion and metastasis of human pancreatic adenocarcinoma cells
Authors: Jinhai Zhu
Xiaoqian Wang
Nanhong Tang
Xiujin Li
Yanlin Chen
Fei Miao
Journal: Oncology letters (2016)
Discipline: CLINICAL MEDICINE
Keywords: SOCS-6; invasion; metastasis; microRNA-183-5p; pancreatic cancer

Abstract:  The aim of the current study was to investigate the potential role of microRNA-183-5p (miR-183-5p) in the proliferation, invasion and metastasis of pancreatic cancer, and to identify promising target genes of oncogenic miR-183-5p. Western blotting and quantitative polymerase chain reaction (qPCR) were used to investigate whether these oncogenic microRNAs may be useful as biomarkers in pancreatic carcinoma (PaCa). Potential target genes were verified using miRDB, PicTar and TargetSCAN, and qPCR was used to detect the expression of miR-183 and suppressor of cytokine signaling 6 (SOCS-6; a potential target of miR-183) in PANC-1 PaCa cells and in the HPDE6-C7 pancreatic ductal cell line for comparison. The function of miR-183 in cell proliferation, wound healing, invasion and migration was also investigated using a miR-183 inhibitor. Western blot analysis was used to confirm SOCS-6 as a tumor suppressor and qPCR was used to detect and confirm that this potential target gene is directly regulated by miR-183. The results indicated that the expression of miR-183 in PANC-1 cells was upregulated compared with that in HPDE6-C7 cells, whilst the expression of SOCS-6 was downregulated. SOCS-6 expression was also significantly lower in PaCa tissues compared with that in matched normal pancreatic tissues from PaCa patients. Furthermore, expression of miR-183 was inversely correlated with that of SOCS-6. miR-183 knockdown decreased cell growth and motility in pancreatic cancer cells and significantly increased the expression of SOCS-6. These data suggest that oncogenic miR-183 may be useful as a pancreatic cancer biomarker. In addition, inhibition of miR-183 expression may be beneficial as PaCa treatment. SOCS-6 is a potential target gene of miR-183. 

Retracted: No

PubPeer comments:
 This paper was found during a systematic search of papers in this journal with possible duplicated images. Fifteen papers in this journal (n=98 examined) were found to contain inappropriately duplicated images. These papers have all been reported to the journal publisher in 2017. The editors promised to  investigate promptly but no action has been taken as of today. Figure 4D. The  NC and  PANC-1 panels appear to show an overlap. Shown with blue boxes. ![file] , 
 #1 Dear Elisabeth M Bik Thank you for your comments, which we have looked into very carefully and discussed. We have checked the original data again and found that it was caused by first authoru2019s careless mistakes.u00a0Since the results of the NC group and the PANC-1 group are similar, they were put in the same folder in the computer at that time. When we prepare the results in the NC chart of Figure 4D, we regret that we accidentally used the chart from the PANC-1 group to represent the NC group while omitting the actual chart of the NC group. We have revisited all the raw data of these experiments, and the data is true and reliable. We sincerely apologize for this unintentional error made before manuscript submission. We have contacted the editorial office of theu00a0ONCOLOGY LETTERS. and We believe that the corrected chart will be published soon. We sincerely apologize for the mistakes that have been made in the paper. Sincerely yours, Fei Miao Zhu jinhai The corrected supplementary Figure 4D and related raw data are attached below. ![file] ![file] ![file] ![file] ![file] ![file] , 
 #1 Hi Elisabeth M Bik In fact, I had replied to the editor of Oncology Letter three years ago and provided relevant correct chart and data. 8 month ago, I failed to timely reply to your comments from Peer, until I receive the email from the edit yesterday. Then I immediately register the website, and answer your comments. I sincerely apologize for the mistakes that have been made in my paper. I hope have the chance to be corrected. Sincerely yours, Fei Miao , 
 Corrigendum, 14 December 2020: https: www.spandidos-publications.com 10.3892 ol.2020.12373  *Subsequently to the publication of this paper, an interested reader drew to the authorsu2019 attention that a pair of data panels contained strikingly similar and overlapping data in Fig. 3D (specifically, the u201cNCu201d and u201cPANCu20111u201d panels). The authors have reu2011examined their data and realized that Fig. 3 was assembled incorrectly. The revised version of Fig. 3, containing the correct data for the u201cNCu201d group in Fig. 3D, is shown on the next page. The authors regret the inadvertent errors that were made during the preparation of the published figure, and confirm that these errors did not seriously affect the conclusions reported in the paper. The authors are grateful to the editor of Oncology Letters for allowing them the opportunity to publish a Corrigendum, and all the authors agree to this Corrigendum. Furthermore, they apologise to the readership for any inconvenience caused. [the original article was published in Oncology Letters 11: 134-140, 2016; DOI: 10.3892 ol.2015.3872]* I thank the authors for trying to correct this error in a timely matter. Still, the time between reporting and the actual Corrigendum was over three years. ,